Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Operating Expenses (2016 - 2026)

Integra Lifesciences Holdings' Operating Expenses history spans 17 years, with the latest figure at $411.9 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 1.2% to $411.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 billion, a 34.54% increase, with the full-year FY2025 number at $2.1 billion, up 34.54% from a year prior.
  • Operating Expenses hit $411.9 million in Q4 2025 for Integra Lifesciences Holdings, up from $390.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for IART hit a ceiling of $928.3 million in Q2 2025 and a floor of $320.1 million in Q3 2022.
  • Historically, Operating Expenses has averaged $390.2 million across 5 years, with a median of $358.4 million in 2023.
  • Biggest five-year swings in Operating Expenses: fell 4.93% in 2022 and later skyrocketed 120.39% in 2025.
  • Tracing IART's Operating Expenses over 5 years: stood at $347.3 million in 2021, then dropped by 4.93% to $330.2 million in 2022, then grew by 9.33% to $361.0 million in 2023, then rose by 12.75% to $407.0 million in 2024, then rose by 1.2% to $411.9 million in 2025.
  • Business Quant data shows Operating Expenses for IART at $411.9 million in Q4 2025, $390.3 million in Q3 2025, and $928.3 million in Q2 2025.